This page shows the latest betrixaban news and features for those working in and with pharma, biotech and healthcare.
The three drugs in question are Portola’s anticagulant Dexxience (betrixaban), Radius’ osteoporosis candidate Eladynos (abaloparatide) and AB Science’s Alsitek (masitinib), filed for neurodegenerative disease amyotrophic lateral sclerosis (ALS)
There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos
for betrixaban, its oral, once-daily Factor Xa inhibitor, as well as antidote drug andexanet alfa. ... Moreover, the CHMP still have concerns about betrixaban that will continue to delay approval, even though it has already been approved by the US FDA as
Merck and Portola Pharmaceuticals have signed an exclusive global collaboration and license agreement for betrixaban. ... for additional royalties and to co-promote betrixaban with Merck in the US.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Betrixaban. Betrixaban (Portola Pharmaceuticals) is a long-acting oral factor Xa inhibitor that entered phase III trial development for VTE prevention in medically ill patients in March 2012. ... Promising phase II results of betrixaban for VTE
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...